Patents by Inventor Mitchell Stuart Gross

Mitchell Stuart Gross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 7982005
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: March 1, 2010
    Date of Patent: July 19, 2011
    Assignee: GlaxoSmithKline LLC
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • RECOMBINANT IL-5 ANTAGONISTS USEFUL IN TREATMENT OF IL-5 MEDIATED DISORDERS
    Publication number: 20100316634
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Application
    Filed: March 1, 2010
    Publication date: December 16, 2010
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
    Patent number: 7807793
    Abstract: Chimeric and humanized IL4 MAbs derived from affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: October 5, 2010
    Assignee: GlaxoSmithKline LLC
    Inventors: Stephen Dudley Holmes, Mitchell Stuart Gross, Daniel R. Sylvester
  • RECOMBINANT IL-5 ANTAGONISTS USEFUL IN TREATMENT OF IL-5 MEDIATED DISORDERS
    Publication number: 20090017020
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Application
    Filed: June 6, 2008
    Publication date: January 15, 2009
    Inventors: Robert S. AMES, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 7399837
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: October 20, 2005
    Date of Patent: July 15, 2008
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham P.L.C.
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 6946130
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: September 20, 2005
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Publication number: 20040156850
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Application
    Filed: November 4, 2003
    Publication date: August 12, 2004
    Applicants: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Publication number: 20030059429
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Application
    Filed: May 13, 2002
    Publication date: March 27, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
    Publication number: 20020193575
    Abstract: Chimeric and humanized IL4 MAbs derived from affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.
    Type: Application
    Filed: June 12, 2001
    Publication date: December 19, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Stephen Dudley Holmes, Mitchell Stuart Gross, Daniel R. Sylvester
  • Anticoagulant agents useful in treatment of thrombosis
    Publication number: 20020146411
    Abstract: Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis are disclosed.
    Type: Application
    Filed: January 17, 2002
    Publication date: October 10, 2002
    Applicant: SmithKline Beecham Corporation
    Inventors: Michael Neal Blackburn, William Robert Church, Giora Zeev Feuerstein, Mitchell Stuart Gross, Andrew John Nichols, Eduardo Agustin Padlan, Arunbhai Haribhai Patel, Daniel Robert Sylvester
  • Anti-factor IX/IXa antibodies
    Patent number: 6391299
    Abstract: Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis are disclosed.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: May 21, 2002
    Assignees: SmithKline Beecham Corporation, University of Vermont and State Agricultural College
    Inventors: Michael Neal Blackburn, William Robert Church, Giora Zeev Feuerstein, Mitchell Stuart Gross, Andrew John Nichols, Eduardo Agustin Padlan, Arunbhai Haribhai Patel, Daniel Robert Sylvester
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 6129913
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: June 19, 1997
    Date of Patent: October 10, 2000
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert S. Ames, Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Nucleic acids encoding immunoglobulin domains
    Patent number: 6005091
    Abstract: Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis are disclosed.
    Type: Grant
    Filed: January 16, 1997
    Date of Patent: December 21, 1999
    Assignees: SmithKline Beecham Corporation, University of Vermont and State Agricultural College
    Inventors: Michael Neal Blackburn, William Robert Church, Giora Zeev Feuerstein, Mitchell Stuart Gross, Andrew John Nichols, Eduardo Agustin Padlan, Arunbhai Haribhai Patel, Daniel Robert Sylvester
  • DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
    Patent number: 5928904
    Abstract: Chimeric and humanized IL4 MAbs derived from high affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: July 27, 1999
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham P.L.C.
    Inventors: Stephen D. Holmes, Mitchell Stuart Gross, Daniel R. Sylvester
  • Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
    Patent number: 5914110
    Abstract: Chimeric and humanized IL4 MAbs derived from high affinity MAbs, pharmaceutical compositions containing same, and methods of treatment are provided.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 22, 1999
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Stephen D. Holmes, Mitchell Stuart Gross, Daniel R. Sylvester
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 5851525
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: September 30, 1997
    Date of Patent: December 22, 1998
    Assignee: SmithKline Beecham Corporation
    Inventors: Robert S. Ames, Jr., Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 5693323
    Abstract: Chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: December 2, 1997
    Assignee: SmithKline Beecham Corporation
    Inventors: Robert S. Ames, Jr., Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen
  • DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
    Patent number: 5683892
    Abstract: DNA encoding chimeric, humanized and other IL-5 mAbs, derived from high affinity neutralizing mAbs, pharmaceutical compositions containing same, methods of treatment and diagnostics are provided.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 4, 1997
    Assignees: SmithKline Beecham Corporation, SmithKline Beecham p.l.c.
    Inventors: Robert S. Ames, Jr., Edward Robert Appelbaum, Irwin M. Chaiken, Richard M. Cook, Mitchell Stuart Gross, Stephen Dudley Holmes, Lynette Jane McMillan, Timothy Wayne Theisen